Compare Estee Lauder Companies Inc (EL) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Estee Lauder Companies Inc vs BIO-TECHNE Corp — how do they compare? Estee Lauder Companies Inc trades at $82.11 (market cap $29.78B), while BIO-TECHNE Corp trades at $71.5 (market cap $11.14B). The key difference: Estee Lauder Companies Inc is far larger — about 2.7× BIO-TECHNE Corp's market cap, and Estee Lauder Companies Inc pays the higher dividend (1.7%). Which is the better fit depends on your goals.
| EL | TECH | |
|---|---|---|
Market Cap | $29.78B | $11.14B |
Sector | Consumer Staples | Health |
52-Week High | $119.61 | $71.48 |
52-Week Low | $67.23 | $43.31 |
Enterprise Value | $35.95B | $11.22B |
Dividend Yield | 1.7% | 0.45% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Estee Lauder Companies Inc
Estee Lauder is the world leader in the global prestige beauty market, participating across skincare (56% of fiscal 2022 sales), makeup (26%), fragrance (14%), and haircare (4%) categories, with popular brands such as Estee Lauder, Clinique, MAC, La Mer, Jo Malone, Aveda, Bobbi Brown, Too Faced, Origins, Dr. Jart+, and The Ordinary. The firm operates in 150 countries, with 26% of fiscal 2022 revenue stemming from the Americas, 43% from Europe, the Middle East, and Africa, and 31% from Asia-Pacific. The company sells its products through department stores, travel retail, multi-brand specialty beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.
Read more on EL →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
